Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Total Valuation
Travere Therapeutics has a market cap or net worth of $1.60B. The enterprise value is $1.40B.
Market Cap$1.60B
Enterprise Value$1.40B
Share Statistics
Travere Therapeutics has 89,138,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding89,138,670
Owned by Insiders1.53%
Owned by Institutions41.13%
Financial Efficiency
Travere Therapeutics’s return on equity (ROE) is -5.44 and return on invested capital (ROIC) is -68.62%.
Return on Equity (ROE)-5.44
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-68.62%
Return on Capital Employed (ROCE)-0.82
Revenue Per Employee605.65K
Profits Per Employee-832.81K
Employee Count385
Asset Turnover0.39
Inventory Turnover1.25
Valuation Ratios
The current PE Ratio of Travere Therapeutics is ―. Travere Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value23.26
Price to FCF―
Price to Operating Cash Flow-13.91
PEG Ratio―
Income Statement
In the last 12 months, Travere Therapeutics had revenue of 233.18M and earned -321.55M in profits. Earnings per share was -4.08.
Revenue233.18M
Gross Profit225.43M
Operating Income-320.63M
Pretax Income-320.51M
Net Income-321.55M
EBITDA-265.77M
Earnings Per Share (EPS)-4.08
Cash Flow
In the last 12 months, operating cash flow was -115.44M and capital expenditures -3.20M, giving a free cash flow of -118.28M billion.
Operating Cash Flow-115.44M
Free Cash Flow-118.28M
Free Cash Flow per Share-1.33
Dividends & Yields
Travere Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change98.01%
50-Day Moving Average16.05
200-Day Moving Average17.99
Relative Strength Index (RSI)59.60
Average Volume (3m)1.47M
Important Dates
Travere Therapeutics upcoming earnings date is Nov 5, 2025, After Close (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date―
Financial Position
Travere Therapeutics as a current ratio of 2.08, with Debt / Equity ratio of 1220.18%
Current Ratio2.08
Quick Ratio2.04
Debt to Market Cap0.28
Net Debt to EBITDA-1.29
Interest Coverage Ratio-28.67
Taxes
In the past 12 months, Travere Therapeutics has paid 120.00K in taxes.
Income Tax120.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Travere Therapeutics EV to EBITDA ratio is -6.46, with an EV/FCF ratio of -5.07.
EV to Sales7.36
EV to EBITDA-6.46
EV to Free Cash Flow-5.07
EV to Operating Cash Flow-7.23
Balance Sheet
Travere Therapeutics has $319.54M in cash and marketable securities with $399.57M in debt, giving a net cash position of $80.04M billion.
Cash & Marketable Securities$319.54M
Total Debt$399.57M
Net Cash$80.04M
Net Cash Per Share$0.90
Tangible Book Value Per Share-$0.57
Margins
Gross margin is 92.69%, with operating margin of -137.51%, and net profit margin of -137.90%.
Gross Margin92.69%
Operating Margin-137.51%
Pretax Margin-137.45%
Net Profit Margin-137.90%
EBITDA Margin-113.98%
EBIT Margin-132.66%
Analyst Forecast
The average price target for Travere Therapeutics is $32.96, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.96
Price Target Upside83.93% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast87.94%
EPS Growth Forecast57.84%